AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02455778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02053558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic lidocaine
Description: Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
Study NCT04751084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buscopan 20 milligrams/ML Injectable Solution
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
Study NCT04751084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan 20 milligrams/ML Injectable Solution
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
Study NCT02027675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat poor micronutrient meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
Study NCT02027675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
Study NCT03986736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis - upon admission
Description: Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
Study NCT03986736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis - 24 hours after injury
Description: Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
Study NCT01935466 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Ever users of Pioglitazone
Study NCT02676362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid collection with filter paper
Description: Gingival Crevicular Fluid Dynamics
Study NCT00698880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right hepatic vein embolization
Description: Embolization of the right hepatic vein
Study NCT00761865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Cast Stirrup Brace & High Tide Fracture Boot
Description: Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
Study NCT02053558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK with ropivacaine
Description: TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
Study NCT03723499 — intervention group
Intervention type: OTHER
Intervention: Medical data collection
Description: Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
Study NCT03859141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
Study NCT03859141 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Victoria strain)
Description: One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
Study NCT03859141 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Yamagata strain)
Description: One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
Study NCT04414761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
Study NCT04414761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH Antagonist
Description: GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study NCT00259272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
Study NCT02232594 — intervention group
Intervention type: DRUG
Intervention: Berodual®
Study NCT01641965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home pressure ventilator model Vivo 40 (BREAS Medical AB)
Description: Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
Study NCT02379611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fNIRS (Functional Near Infrared Spectroscopy)
Description: fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Study NCT02379611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS (Functional Near Infrared Spectroscopy)
Description: fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Study NCT04628273 — intervention group
Intervention type: PROCEDURE
Intervention: encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy
Study NCT05148169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRIs
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
Study NCT05148169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
Study NCT05148169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SSRI plus Sulforaphane
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening.
Study NCT04806529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)
Description: Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
Study NCT02326389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
Study NCT02326389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
Study NCT02326389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
Study NCT01227304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCCO-parameter-guided volume challenge
Description: Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
Study NCT03771443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental gluten free toothpaste
Description: we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
Study NCT03162029 — intervention group
Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging of participants, then take measurement by radiomorphometric indices
Study NCT03274180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing consultation
Description: travel preventive consultation was performed by nurse
Study NCT03965871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - low dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
Study NCT03965871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - medium dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
Study NCT03965871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - high dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
Study NCT03965871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI is to be administered via dry powder inhaler.
Study NCT01645865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
Study NCT01645865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
Study NCT01999907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
Study NCT01999907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: daily vitamin D supplement
Description: Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
Study NCT01999907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: daily vitamin D supplement
Description: Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
Study NCT03068260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound-guided nerve block
Description: Transmuscular quadratus lumborum block, ultrasound-guided
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump
Study NCT03068260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
Study NCT03068260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
Study NCT00134082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KGEL vaccine
Description: Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
Study NCT04163653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: Classification and characterization of the lymphatic vasculature using non-contrast MRI.
Study NCT00134082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg/day starting on Day +6 until ANC is >= 1000/mcL.
Study NCT00134082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
Study NCT01999907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given in a 2ml dose by mouth at baseline.
Study NCT01146951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide (E2080)
Description: Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
Study NCT04163653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Cardiopulmonary exercise test, measurement of VO2 and heart rate.
Study NCT02186782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Estradiol
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Study NCT02186782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Placebo
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
Study NCT02439905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Study NCT04806529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
Study NCT02439905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Study NCT03117114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision assisted polypectomy
Description: EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
Study NCT03117114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard polypectomy
Description: Absence of an EVD, standard polypectomy
Study NCT01976871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
Study NCT01381471 — intervention group
Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate combination
Description: fluticasone propionate/salmeterol xinafoate combination
Study NCT00780234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence bronchoscopy
Description: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
Study NCT01146951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Study NCT03235726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Study NCT03235726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Study NCT03498118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL of bupivacaine 0.25%
Description: In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
Study NCT03498118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mL of bupivacaine 0.25%
Description: In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
Study NCT02771457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab at weeks 0,2, and 6
Study NCT02771457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab at weeks 0,4, and 8
Study NCT00780234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fluorescence bronchoscopy
Description: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
Study NCT00780234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quantitative high resolution CT scan
Description: High resolution CT scan of the chest
Study NCT00780234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quantitative high resolution CT scan
Description: High resolution CT scan of the chest
Study NCT00134082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day on Day -3, -2, -1, and 0.
Study NCT03011736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03011736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Description: Undergo parathyroidectomy